Search results
Showing 1 to 15 of 64 results for ulcerative colitis
This guideline covers managing ulcerative colitis in children, young people and adults. It aims to help professionals to provide consistent high-quality care and it highlights the importance of advice and support for people with ulcerative colitis.
This guideline covers using colonoscopy to check for signs of bowel cancer in people aged 18 and over with ulcerative colitis or Crohn’s disease (types of inflammatory bowel disease) or adenomas (also known as polyps). It aims to prevent cancer and prolong life by offering advice on identifying early bowel cancer in adults most at risk.
Infliximab for acute exacerbations of ulcerative colitis (TA163)
Evidence-based recommendations on infliximab (Remicade) for treating acute exacerbations of severely active ulcerative colitis in adults.
Tofacitinib for moderately to severely active ulcerative colitis (TA547)
Evidence-based recommendations on tofacitinib (Xeljanz) for previously treated moderately to severely active ulcerative colitis in adults.
Upadacitinib for treating moderately to severely active ulcerative colitis (TA856)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating moderately to severely active ulcerative colitis in adults.
Ozanimod for treating moderately to severely active ulcerative colitis (TA828)
Evidence-based recommendations on ozanimod (Zeposia) for treating moderately to severely active ulcerative colitis in adults when conventional or biological treatments cannot be tolerated or are not working well enough.
Vedolizumab for treating moderately to severely active ulcerative colitis (TA342)
Evidence-based recommendations on vedolizumab (Entyvio) for treating moderate to severe ulcerative colitis in adults.
Filgotinib for treating moderately to severely active ulcerative colitis (TA792)
Evidence-based recommendations on filgotinib (Jyseleca) for moderately to severely active ulcerative colitis in adults when conventional or biological treatment cannot be tolerated, or the disease has responded inadequately or lost response to treatment.
Risankizumab for treating moderately to severely active ulcerative colitis (TA998)
Evidence-based recommendations on risankizumab (Skyrizi) for treating moderately to severely active ulcerative colitis in adults.
Evidence-based recommendations on etrasimod (Velsipity) for moderately to severely active ulcerative colitis in people aged 16 and over.
Mirikizumab for treating moderately to severely active ulcerative colitis (TA925)
Evidence-based recommendations on mirikizumab (Omvoh) for treating moderately to severely active ulcerative colitis in adults.
Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.
Ustekinumab for treating moderately to severely active ulcerative colitis (TA633)
Evidence-based recommendations on ustekinumab (Stelara) for treating moderately to severely active ulcerative colitis in adults.
This quality standard covers diagnosing and managing inflammatory bowel disease (Crohn’s disease and ulcerative colitis) in adults, young people and children. It describes high-quality care in priority areas for improvement.
NICE is unable to make a recommendation on vedolizumab (Entyvio) for treating chronic refractory pouchitis after surgery for ulcerative colitis in adults. This is because Takeda did not provide an evidence submission.
Show all sections
Sections for TA826